Kacin 100 mg Injection: Each 2ml ampoule contains Amikacin 100 mg as Sulfate USP.
Kacin 250 mg Injection: Each 2ml ampoule contains Amikacin 250 mg as Sulfate USP.
Kacin 500 mg Injection: Each 2ml ampoule contains Amikacin 500 mg as Sulfate USP.
Kacin® is the preparation of Amikacin which is an aminoglycoside, binds to the prokaryotic ribosome, inhibiting protein synthesis in susceptible bacteria. It is bactericidal in vitro against gram positive and gram negative bacteria.
Uses Kacin ® is a semi-synthetic aminoglycosidic antibiotic, indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria. Kacin ® is effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra abdominal infections (including peritonitis); and in burns and post operative infections (including postvascular surgery). Kacin ® is also effective in serious complicated and recurrent urinary tract infections due to susceptible Gram-negative organisms. Kacin ® may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility. Kacin ® is also effective in infections caused by Gentamycin and/or Tobramycin resistant strains of Gram-negative organisms. Kacin ® has also been shown to be effective in Staphylococcal infection and may be considered as initial therapy under certain condition in the treatment of known suspected Staphylococcal disease such as, severe infections where the causative organism may either a Gram-negative bacterium or Staphylococcus infection due to susceptible strains of Staphylococcal / Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin type drug may be indicated because of the possibility of infections due to Gram positive organism such as streptococci or pneumococci.
Route of administration: For most infections the intramuscular route is preferred, but in life threatening infections or in patients in whom intramuscular injection route is not feasible the intravenous route may be used. Kacin® is also given in intraperitoneal route and is used as an irrigant after recovery from anesthesia in concentration of 0.25%.
Adults and children: 15 mg/kg/day in two equally divided doses (equivalent to 500 mg bid in adults).
Neonates and premature children: An initial loading dose of 10 mg/kg followed by 15 mg/kg/day in two equally divided doses.
Elderly : Doses should be adjusted under impaired renal function in elderly.
Life threatening infections and/or those caused by pseudomonas: The adult dose may be increased to 500 mg every eight hours but should neither exceed 1.5 g/day nor be administered for a period longer than 10 days. A maximum total adult dose of 15 g should not be exceeded.
Urinary tract infection (other than pseudomonal infections): 7.5 mg/kg/day in two equally divided doses (equivalent to 250 mg bid in adults).
Impaired renal function:
Mild impairment: 500 mg every 18 hours
Moderate impairment: 500 mg every 24 hours
Severe impairment: 250 mg every 24 hours
Concomitant nephrotoxic and ototoxic drugs (furosemide, cisplatin, vancomycin, amphotericin B) cause additive organ toxicity; enhances neuromuscular blockade of succinylcholine and tubocurarine.
Amikacin is contraindicated in patients with known hypersensitivity to amikacin or any components of this product.
Common: Tinnitus, vertigo, partial reversible/irreversible deafness, skin rash, drug fever, headache, paresthesia, nausea, vomiting. Less Common: Nephrotoxicity (azotemia, oliguria, urinary signs of renal irritation).
Overdose
In case of overdose, peritoneal dialysis or hemodialysis will aid in the removal of amikacin from
the blood. In the newborn infant exchange transfusion may also be considered.
Category D. Aminoglycosides cross the placenta and can cause irreversible bilateral congenital deafness; use only in life-threatening infections. Lactation: Excretion in human milk unknown; discontinue nursing or discontinue drug.
Store below 25°C in a cool, dry place. Protect from light. Keep away from the reach of children.